Neurocrine Biosciences (NBIX-0.41%) generated $959 million in revenue in Q2 2026, representing an increase of 39% year over ...

On October 7, 2026, Cerevance announced the top-line results of the Phase 3 ARISE trial for the investigational Parkinson's ...

Alongside medical treatment, adopting healthy habits can help you manage tardive dyskinesia. Find out what experts recommend.

Tardive Dyskinesia (TD) doesn’t just change the way the body moves. It also changes the way we view that body, in mirrors, in ...

The FDA approved Juvmo, a once-daily tavapadon pill that selectively activates D1 and D5 dopamine receptors, for adults with ...

ALPHA | Overview of Technology◾️What is Neurocrine Biosciences' SciTech?Pharmaceutical technology targeting neurotransmission ...

Mentara Therapeutics, a new neuropsychiatry company backed by SPRIM Global Investments, today launched with the acquisition of EM-221, ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of ...

A stunning video capturing intricate cell movement in a child living with a rare genetic disorder has won the 16th annual Nikon Small World in Motion competition. Using an advanced microscopic imaging ...

DEAR DR. ROACH: I’m a 66-year-old retired female who’s trying to keep active. My neurologist thinks that I may have tardive dyskinesia (TD), for which I tried Ingrezza, but I experienced heaviness in ...

Tardive dyskinesia (TD) is a persistent sensorimotor syndrome associated with antipsychotic exposure in schizophrenia spectrum disorders (SSD) and mood disorders (MOD), yet its neurobiological basis ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...